SCaN: A Screening and Characterization Platform for Nanosuspensions Enables In Vivo Delivery of a Crystalline hRpn13Pru Degrader
{{output}}
Proteolysis-targeting chimeras (PROTACs) and degraders have been developed against the hRpn13 fragment hRpn13Pru that is present in various cancer types. Testing the performance of these hRpn13Pru-targeting compounds in pharmacokinetic and efficacy studies has... ...
